Abstract

Neoadjuvant chemotherapy (NAC) has emerged as a pivotal strategy in the management of early-stage cervical cancer, particularly for patients undergoing radical trachelectomy. This article reviews the rationale and effectiveness of NAC as a means to enhance surgical outcomes by facilitating tumor shrinkage, enabling downstaging of disease, and allowing for the assessment of tumor chemosensitivity prior to surgery. Clinical evidence indicates that NAC can lead to improved surgical outcomes, including higher rates of negative margins and reduced recurrence rates. However, careful patient selection, management of chemotherapy-related toxicities, and coordinated treatment planning are essential for optimizing patient benefits. As ongoing research continues to explore the long-term implications of NAC, this approach holds promise for improving treatment outcomes in women with cervical cancer while preserving fertility. This review emphasizes the importance of a multidisciplinary approach in implementing NAC alongside radical trachelectomy to achieve favorable oncological results and enhance quality of life for patients.